[
  {
    "ts": null,
    "headline": "Vertex Pharmaceuticals (VRTX) Stock Dips While Market Gains: Key Facts",
    "summary": "In the most recent trading session, Vertex Pharmaceuticals (VRTX) closed at $463.86, indicating a -1.24% shift from the previous trading day.",
    "url": "https://finnhub.io/api/news?id=66936a1694f4d4522cc191661b19de07e6de809867141159ce6880944c602982",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767999004,
      "headline": "Vertex Pharmaceuticals (VRTX) Stock Dips While Market Gains: Key Facts",
      "id": 138052543,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "In the most recent trading session, Vertex Pharmaceuticals (VRTX) closed at $463.86, indicating a -1.24% shift from the previous trading day.",
      "url": "https://finnhub.io/api/news?id=66936a1694f4d4522cc191661b19de07e6de809867141159ce6880944c602982"
    }
  },
  {
    "ts": null,
    "headline": "Does Vertex Pharmaceuticals (VRTX) Share Price Reflect Its Long Term Growth Potential?",
    "summary": "If you are wondering whether Vertex Pharmaceuticals' current share price reflects its long term potential, a useful starting point is to understand how the market is valuing its future cash flows and growth prospects. Vertex Pharmaceuticals' stock recently closed at US$469.68, with returns of 3.6% over the past week, 7.5% over the past month, 3.9% year to date, 14.0% over the past year, 58.5% over three years and 107.7% over five years. These figures may influence how investors think about...",
    "url": "https://finnhub.io/api/news?id=d05629e617d3a3b5104efd06f95916f71976553a6e561a2f13a2de5dea4b5dcd",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767989518,
      "headline": "Does Vertex Pharmaceuticals (VRTX) Share Price Reflect Its Long Term Growth Potential?",
      "id": 138052545,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "If you are wondering whether Vertex Pharmaceuticals' current share price reflects its long term potential, a useful starting point is to understand how the market is valuing its future cash flows and growth prospects. Vertex Pharmaceuticals' stock recently closed at US$469.68, with returns of 3.6% over the past week, 7.5% over the past month, 3.9% year to date, 14.0% over the past year, 58.5% over three years and 107.7% over five years. These figures may influence how investors think about...",
      "url": "https://finnhub.io/api/news?id=d05629e617d3a3b5104efd06f95916f71976553a6e561a2f13a2de5dea4b5dcd"
    }
  },
  {
    "ts": null,
    "headline": "Assessing Vertex Pharmaceuticals (VRTX) Valuation After Wolfe Research Upgrade And Growing Pipeline Optimism",
    "summary": "Vertex Pharmaceuticals (VRTX) is back in focus after Wolfe Research upgraded the stock to Outperform, citing increased confidence in its investigational IgA nephropathy therapy and plans to use a priority review voucher. See our latest analysis for Vertex Pharmaceuticals. The Wolfe upgrade comes after a solid run, with a 90 day share price return of 15.18% and a 1 year total shareholder return of 13.97%. This suggests momentum has been building around Vertex’s pipeline story beyond cystic...",
    "url": "https://finnhub.io/api/news?id=59bae53ed4c21c5850126ed160fb3cc3d7b6361fc95f7ad8961f8c6579628d79",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767971618,
      "headline": "Assessing Vertex Pharmaceuticals (VRTX) Valuation After Wolfe Research Upgrade And Growing Pipeline Optimism",
      "id": 138046736,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "Vertex Pharmaceuticals (VRTX) is back in focus after Wolfe Research upgraded the stock to Outperform, citing increased confidence in its investigational IgA nephropathy therapy and plans to use a priority review voucher. See our latest analysis for Vertex Pharmaceuticals. The Wolfe upgrade comes after a solid run, with a 90 day share price return of 15.18% and a 1 year total shareholder return of 13.97%. This suggests momentum has been building around Vertex’s pipeline story beyond cystic...",
      "url": "https://finnhub.io/api/news?id=59bae53ed4c21c5850126ed160fb3cc3d7b6361fc95f7ad8961f8c6579628d79"
    }
  },
  {
    "ts": null,
    "headline": "Prediction: 2 Healthcare Stocks That Will Be Worth More Than Pfizer by the End of 2026",
    "summary": "It could be another tough year for the once-soaring drugmaker.",
    "url": "https://finnhub.io/api/news?id=671086fc2166b8182cea8c946e5ccae67960b29adc6b689890d9c99fb800b77f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767970200,
      "headline": "Prediction: 2 Healthcare Stocks That Will Be Worth More Than Pfizer by the End of 2026",
      "id": 138046728,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "It could be another tough year for the once-soaring drugmaker.",
      "url": "https://finnhub.io/api/news?id=671086fc2166b8182cea8c946e5ccae67960b29adc6b689890d9c99fb800b77f"
    }
  }
]